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SUMMARY
Background and Aims: Experimental autoimmune encephalomyelitis (EAE) is T-cell-
dependent disease of the central nervous system (CNS) of mice. This model resembles mul-
tiple sclerosis (MS) in many aspects. Therapies that focus in the modulation of the immune
response and cellular infiltration in the CNS present best effects in the clinics. Artesunate
(Art) is a semi-synthetic sesquiterpene derivative from artemisinin and has been shown to
reduce the clinical signs of autoimmune disease models through mechanisms not yet under-
stood. In this study, we aimed to evaluate whether administration of Art would ameliorate
EAE. Methods and Results: C57BL6 mice were immunized with MOG35–55 peptide to
induce EAE. At the same time, Art treatment started (3 mg/kg/day via i.p.) for five consecu-
tive days. We found that Art treatment reduced the clinical signs of EAE and that correlated
with a reduced infiltration of cells in the CNS. Disease amelioration did not correlate with
immunomodulation as recall responses, leukocyte subpopulations, and gene expression
analysis were similar among treated and untreated mice. Ultimately, further analysis pro-
vided data indicating that a possible mechanism of action for Art is dependent on the cellu-
lar migration to the CNS. Conclusions: Artesunate reduces the severity of EAE by
inhibiting migration of pathogenic T cells to the CNS.
Introduction
Multiple sclerosis (MS) is a human demyelinating disease charac-
terized by clinical signs that include paralysis, ataxia, and even
death. MS is believed to affect more than 2 million people world-
wide. The etiology of the disease is not completely understood but
self-aggression against the components of the central nervous sys-
tem (CNS) by leukocytes is believed to play a major role [1,2].
There are three main types of manifestation of MS: primary pro-
gressive (PP-MS), secondary progressive (SP-MS), and relapsing–
remitting (RR-MS) [3]. In all forms, the outbreak of symptoms is
associated with migration of encephalitogenic leukocytes to the
CNS [4]. Experimental autoimmune encephalomyelitis (EAE) is a
T-cell-mediated disease that shares many aspects with MS [5–7].
Although interferon-gamma-producing helper 1 T (Th1) cells are
important orchestrators of inflammation, EAE is also dependent on
IL-17-producing Th17 cells, where ablation of IL-17 production/
signaling ameliorates disease [8–13]. The inflammation caused by
infiltrating T cells worsens the disease. In this context, the
administration of migration inhibitors, such as fingolimod and
natalizumab, has been shown to improve patients’ conditions [14–
17]. These observations reinforce the need for the development of
new drugs that target cell migration to the CNS in MS [18].
Many drugs that were used in the treatment of infections have
discovered new uses in the amelioration of inflammation, which
is the case of chloroquine, primaquine, dihydroxyartemisinin, and
artesunate, among others [19–24]. Artesunate (Art), a semi-syn-
thetic sesquiterpene derived from Artemisia annua L., has origi-
nally been used in the treatment of malaria [25,26]. Studies have
shown that Art treatment reduced the severity of autoimmune
diseases, such as rheumatoid arthritis, lupus, and ulcerative colitis
[27–29]. Although the precise mechanism of action exerted by Art
remains to be elucidated, it has been observed that Art treatment
reduced the secretion of mediators of inflammation as inflamma-
tory cytokines (IL-17, TNF-a, IFN-c, IL-6), germinal center B cells,
and proliferation of T cells [27–29].
In this study, we aimed to evaluate whether artesunate admin-
istration would reduce the clinical signs of EAE. We found that
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mice receiving Art in a therapeutic regimen presented a mild EAE
compared with untreated mice. Although the leukocytes subsets
were investigated, we found that Art treatment does not alter the
frequency of key cellular subsets of the EAE-mediated inflamma-
tion. Interestingly, expression of chemokine receptors was found
reduced in T cells as well as the migratory ability of leukocytes from
Art-treated mice. Taken together, our data present a novel mecha-
nism of action exerted by artesunate: the inhibition of the migra-
tory ability of inflammatory cells to the CNS of EAE-inflicted mice.
Materials and Methods
Animals
In total, 6- to 8-week-old female C57BL/6 and RAG2/ mice
were acquired from Centro Multidisciplinar para Investigac~ao
Biologica na Area da Ciência de Animais de Laboratorio (CEMIB,
University of Campinas). Mice were allocated in specific pathogen-
free conditions, in cages (maximum 5mice per cage) with free food
and autoclaved tap water in a controlled photoperiod (12-h/12-h
dark/light cycle) environment. All procedures were performed in
ways that minimize animal suffering. The institutional ethics com-
mittee (University of Campinas Committee on the Use and Care of
Animals—CEUA) approved all experiments under registration
#3345-1(A).
Experimental Autoimmune Encephalomyelitis
induction
For active EAE
Disease was induced in mice according to a previously described pro-
tocol [30]. Briefly, mice were immunized with 100 lg of MOG35–55
peptide (Genscript, Piscataway Township, NJ, USA) emulsified in
complete Freund’s adjuvant (CFA; Sigma-Aldrich, St Louis, MO,
USA) through s.c. injection in the tail base. About 200 ng of
pertussis toxin (Ptx; Sigma) was administrated via i.p. at 0 and 48 h
following immunization. Mice were accompanied daily for the
development of EAE. The clinical signs were evaluated based on
score, in which: 0, no signs of inflammation; 1, limp tail; 2, limp tail
and weakness of the hind limb; 3, paralysis of hind limb; 4; paralysis
of hind limb and weakness of fore limb; and 5, full paralysis/dead.
For passive EAE
C57BL/6 mice were immunized with 100 lg of MOG35–55 peptide
emulsified in CFA through s.c. injection. After 8 days of immu-
nization, mice were killed and erythrocyte-free splenocytes were
prepared. 5 9 106 cells were transferred to each RAG2/ mice
through the i.v. route. About 200 ng of Ptx was administrated via
i.p. at 0 and 48 h following adoptive cell transfer. Mice were
accompanied daily for the development of EAE. The clinical signs
were evaluated as mentioned above.
Artesunate Treatment
Artesunate treatment followed directions from the World Health
Organization [31], with modifications. Artesunate (Sigma) was
dissolved in phosphate-buffered saline (PBS) 0.02M pH7.2. In all
treatment regimens, Art was administrated via i.p. for five consec-
utive days. Each mouse was treated with Art at a concentration of
3 mg/kg/dose. For evaluation of Art on EAE severity, treatment
started on the day EAE was induced. For therapeutic treatment,
Art was administrated from day 10 to day 14 after immunization.
For prophylactic treatment, Art was administrated starting 7 days
before EAE induction. Artesunate half-life after ingestion has
been determined elsewhere [32].
Analysis of the Cellular Infiltration in the CNS
The analysis of cellular infiltration in the CNS of EAE-bearing mice
was performed according to a previously described methodology
with small modifications [33]. Briefly, at the end of the experi-
ment, mice were killed and the CNS was removed and disrupted in
RPMI 1640 medium supplemented with 10% fetal calf serum
(FCS). The suspension was filtered in 70-lm cell strainer (BD Bio-
sciences, Franklin Lakes, NJ, USA) and enriched in isotonic Percoll
(Sigma, GER) gradient (70/30) centrifugation (300 g for 30 min at
4°C without brakes). Cells from the interface were collected and
washed in FACS staining buffer (PBS + 3% FCS). Cellular concen-
tration was calculated with the aid of a hemocytometer. Samples
were submitted to flow cytometry staining or otherwise stated.
Flow Cytometry Analysis of Cellular
Subpopulations
Single-cell suspensions were prepared in FACS staining buffer
(PBS + 3% FCS). 1 9 106 cells were transferred to conical tubes
(12 9 75 mm; BD Biosciences) and incubated with fluo-
rochrome-conjugated antibodies at a final volume of 100 lL for
20 min at 4°C (1 lg antibody/1 million cells). For intracellular
staining of cytokines, 1 9 106 cells from each mice were incu-
bated for 4 h with phorbol-12-myristate-13-acetate (PMA, 50 ng/
mL; Sigma) and ionomycin (500 ng/mL; Sigma) in the presence
of brefeldin A (BFA, 1 lg/mL; BD Biosciences). Later, cells were
surface stained with monoclonal antibodies and permeabilized
with Fix/Perm buffer (eBioscience, San Diego, CA, USA). The
intracellular antigens were stained with fluorochrome-conjugated
antibodies for 20 min at room temperature. Antibodies used in
this study were anti-CD3e (clone 145-2C11), anti-NK1.1 (clone
PK136), anti-CD11c (clone N418), anti-CD4 (clone GK1.5), anti-
CD8 (clone 53-6.7), anti-CCR7 (clone 4B12), anti-CXCR4 (clone
2B11), anti-CCR9 (clone eBioCW-1.2), anti-CD25 (clone PC61),
anti-Foxp3 (clone FJK-16s), anti-IL-10 (clone JES5-16E3), anti-
IFN-c (clone XMG1.2), and anti-IL-17 (clone eBio17B7). All anti-
bodies were from eBiosciences. Preparations (at least 100.000
events) were acquired on Gallios flow cytometer (Becman Coul-
ter, Inc, Jersey City, NJ, USA). Data were analyzed with FlowJo
VX platform (Tristar Inc, Flow Jo LLC, Ashland, OR, USA).
Gene Expression Analysis
Gene expression analysis was performed as previously described
[34]. Briefly, RNA was extracted from tissues using TRIzol reagent
according to manufacturer’s recommendations (Life Technologies,
Carlsbad, CA, USA). About 1 lg of pure RNA was used to prepare
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cDNA according to manufacturer’s recommendations (High-
Capacity kit; Life Technologies). RT-PCRs were conducted
with Taqman reagents according to manufacturer’s protocol
(Life Technologies). Genes investigated in this study were
CCL19 (Mm00839967_g1), CCR7 (Mm99999130_s1), IL-10
(Mm01288386_m1), Foxp3 (Mm00475162_m1), and IL-17
(Mm00439618_m1). Results are shown as relative expression
(2
DDCT).
Recall Response Assays
Analysis of specific cellular proliferation was conducted as previ-
ously described [35]. Briefly, mice were killed at determined time-
points and draining lymph nodes were collected and disrupted to
prepare single-cell suspensions. Cells (5 9 105) were seeded to
each well of a 96-flat bottom well plate with RPMI 1640 medium
supplemented with 10% FCS. For specific proliferation, cells were
cultured in the presence of several concentrations of MOG35–55
peptide (Genscript). The plates were incubated for 96 h at 37°C.
After the incubation period, the cultures were treated with 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT;
Sigma-Aldrich) for 4 h and the formazan crystals dissolved with
isopropanol. Absorbances were read at 540 nm by spectropho-
tometer.
Migration Assays
Evaluation of the cellular migration ability was performed in 24-
transwell plates containing inserts with a pore size of 5 lm (Corn-
ing Life Sciences, Pittston, PA, USA). Briefly, 5 9 105 cells from
draining lymph nodes were seeded in the upper chamber in a final
volume of 100 lL in RPMI 1640 supplemented with 10% FCS.
The lower chamber was filled with 500 lL of medium containing
recombinant mouse 10 ng of CCL19 chemokine (R&D Systems
Inc., Minneapolis, MN, USA). As controls, some cells in the lower
chamber received only medium. The plates were incubated for
3 h at 37°C. At the end of culture time, the cells in the lower
chamber were counted in hemocytometer. In a set of experi-
ments, cells from EAE-bearing mice were allowed to migrate in
the presence of artesunate (2.5 lM; Sigma).
Statistical Analysis
For clinical scores of EAE, data were analyzed by two-way ANOVA
with Bonferroni post-test. Analysis with three or more groups was
performed with one-way ANOVA and Bonferroni post-test. Analy-
sis between two groups was performed with Student’s t-test. Results
are expressed as mean  standard error mean (SEM), unless other-
wise stated. All analyses were carried out in GraphPad Prism soft-
ware (version 6.0, GraphPad Software Inc., La Jolla, CA, USA).
Results
Amelioration of EAE in Art-Treated Mice Does
not Correlate with Altered Leukocyte
Subpopulations that Infiltrate the CNS
To evaluate whether artesunate presents a protective effect in
EAE, we treated C57BL/6 female mice with Art (3 mg/kg) at
the same time of MOG35–55 immunization. In this study, Art
treatment is composed of five consecutive doses administrated
on a daily basis. We found that Art treatment reduced the
Figure 1 Treatment with artesunate reduces the severity of EAE. Experimental autoimmune encephalomyelitis (EAE) was induced in C57BL/6 mice (n = 10)
through the immunization with 100 lg of MOG35–55 peptide and 200 ng/mice of pertussis toxin injection at 0 and 48 h from immunization. Mice were
divided in two groups, where one group received artesunate (3 mg/kg) for five consecutive days starting the same day of immunization and the other group
received vehicle (PBS 0.02M pH7.4). (A) The clinical score was assessed daily and shows that Art-treated mice developed milder EAE. Results are shown as
group mean for each time-point. *P < 0.05 in two-way ANOVA multiple comparison test. (B) Cellular infiltration in the CNS of EAE-bearing mice was
determined after Percoll gradient enrichment of leukocytes and shows reduced infiltration of cells in the CNS of Art-treated mice. *P < 0.05 in t-test analysis.
(C) Flow cytometry analysis of the subpopulations of infiltrating cells of the CNS. Results from four independent experiments with similar observations.
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overall severity of EAE compared with untreated mice (Fig-
ure 1A). Disease amelioration correlated with a reduction in
the infiltration of leukocytes in the CNS of EAE-bearing mice
(Figure 1B). Although the absolute number of infiltrating cells
was reduced in EAE + Art mice, there was no alterations in
the frequency of leukocyte subpopulations that infiltrated the
CNS among groups (Figure 1C).
Artesunate Increased the Frequency of IL-10-
Producing T Cells, Altered the Cellular and
Tissue Expression of Chemokines, yet
Lymphocytes Remained Responsive to
Encephalitogenic Stimulus
As Art treatment did not change the frequency of leukocytes in
the CNS, albeit reduced total infiltration, we aimed to evaluate
whether the cytokine secretion profile of CD4+ T cells was altered
after treatment. We found that the frequency of IL-10-producing
CD4+ T cells doubled in Art-treated compared with untreated
EAE-bearing mice (Figure 2A). Frequencies of IFN-c- and IL-17-
producing CD4+ T cells and regulatory T cells were unaltered after
Art treatment (Figure 2A). Of note, the protein expression of the
chemokine receptors CCR7 and CXCR4, but not CCR9, in CD3+ T
cells was reduced in treated mice (Figure 2B). As it seemed that
components of the cellular migration presented alterations, we
aimed to evaluate the gene expression of chemokine receptors
and ligands as well as mediators of inflammation in the CNS at the
peak of disease severity (14 dpi) and in draining lymph nodes
(dLN) in the preclinical stage of disease (10 dpi). We found that
CNS from Art-treated mice presented a reduction in the expres-
sion of CCR7 and IL-17 compared to untreated mice while gene
expression levels of CCL19, IL-10, and Foxp3 remained unaltered
(Figure 2C). Interestingly, there was no significant change in the
expression of these parameters in dLN from treated and untreated
mice, with the exception of Foxp3 (Figure 2C). The results suggest
that the cellular migration toward the CNS may be compromised
after artesunate treatment. Indeed, we found an augmented cellu-
larity of spleens and dLN from Art + EAE mice compared with
untreated EAE mice after 20 days from MOG35–55 immunization
(Figure 2D). To test whether Art treatment modified the cellular
Figure 2 EAE amelioration in Art-treated mice correlates with leukocyte retention in secondary lymphoid organs but not with altered lymphocyte
subpopulations in the CNS. EAE-bearing mice (n = 5/each group) were killed 20 days after immunization, and the brain and lumbar spinal cords were
collected and submitted to gradient centrifugation to enrich infiltrating leukocytes. (A) To detect intracellular cytokines, cells were activated with PMA and
ionomycin in the presence of brefeldin A (50 ng/mL, 500 ng/mL, and 1 lg/mL, respectively) for 4 h at 37°C. Later, cells were surface stained and
permeabilized for intracellular staining. (B) Infiltrating T cells were surface stained for the analysis of CCR7, CXCR4, and CCR9 by flow cytometry. (C) CNS was
collected from EAE-bearing mice at 14 dpi, whereas draining lymph nodes were collected at 10 dpi. Tissues were submitted to RNA extraction and cDNA
production. Analysis of genetic expression of genes of interest was carried out. *P < 0.05 in t-test analysis. (D) Twenty days after disease induction, mice
were killed and the cellularity of spleens and draining lymph nodes were determined. *P < 0.05 in t-test analysis. (E) Ten days after MOG immunization, mice
were killed and the cells from dLN were collected and cultivated in the presence of increasing doses of MOG35–55. Cells were incubated for 96 h at 37°C.
Proliferation was determined through MTT method. Combined results from five independent experiments with similar observations.
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immune response to neuro-antigens, 10 days after immunization,
we stimulated dLN-derived cells with increasing concentrations of
MOG35–55 and assessed the recall response. We found that
lymphocytes from untreated and Art-treated mice retained their
proliferative response toward the specific neuro-antigen
(Figure 2D).
Artesunate is Efficient only When Administrated
in Specific Time-Points During EAE Development
Our results so far showed that EAE-Art mice developed a mild
EAE compared with untreated mice. We also found that the cellu-
lar immune response toward encephalitogenic peptide and the
subpopulations the infiltrated the CNS remained unchanged in
both groups. The main difference among treated and untreated
mice was the reduced expression of chemokine receptors by T cells
and the retention of cells in the secondary lymphoid organs in
EAE + Art group. Therefore, we aimed to evaluate the “window
of effectiveness” of Art. For that purpose, we started the treatment
1 week before EAE induction (Figure 3A) or at disease onset (Fig-
ure 3B). Our data showed that the prophylactic treatment was
not efficient in reducing disease severity (Figure 3A). However,
treatment at the start of the symptoms was effective and signifi-
cantly reduced the severity of EAE (Figure 3B), although not to
the same extent as when treatment started at day 0 of EAE (Fig-
ure 1A). To exclude the possibility of a potential immune-modu-
latory profile of Art, we treated na€ıve mice for five consecutive
days and evaluated the subpopulations of T lymphocytes in sec-
ondary lymphoid organs as well as the production of cytokines by
CD4+ T cells. We found that treatment with Art did not change
the cellularity of spleens nor did change the frequency of CD4+,
CD8+ and regulatory T cells (Figure 3C). Intracellular production
of IL-10 by na€ıve CD4+ T cells was unaltered, which is in contrast
to what we observed in infiltrating cells in the CNS of EAE + Art
mice (Figure 2A). IFN-c production presented the same pattern as
of infiltrating cells in the CNS of EAE + Art (Figure 2A). These
(A)
(C) (D)
(B)
Figure 3 Administration of artesunate is only effective during inflammation. (A) Artesunate (3 mg/kg) was i.p. administrated to mice for five consecutive
days in a prophylactic regimen starting 7 days before EAE induction. The clinical course of disease was evaluated daily and shows no alteration compared
to untreated mice. (B) Art was administrated for five consecutive days starting on EAE onset (around day 10). Disease course was evaluated daily.
*P < 0.05 in two-way ANOVA multiple comparison test. (C) Na€ıve mice were treated with Art via i.p. for five consecutive days. As controls, mice received
PBS through the same route. At the last day of treatment, spleen cellularity and the T lymphocyte subpopulations were analyzed by flow cytometry. (D)
Following Art treatment, na€ıve and treated mice were killed and the spleens were collected and cells were activated with PMA, ionomycing, and brefeldin
A (50 ng/mL, 500 ng/mL, and 1 lg/mL, respectively) for 4 h. Later, surface and intracellular antigens were stained with fluorochrome-conjugated
antibodies and analyzed by flow cytometry. Combined data from three independent experiments with similar results.
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results confirm that the beneficial effects of artesunate are
obtained on a certain “window of opportunity” and that it is inde-
pendent on an immune-modulatory activity.
Disease Amelioration in Artesunate-Treated
Mice Relies on Inhibition of Leukocyte Migration
Our results suggest that the mechanism of action exerted by arte-
sunate is dependent on the inhibition of leukocyte infiltration on
the CNS rather than the modulation of the immune response. To
test this hypothesis, we obtained dLN cells from EAE and
EAE + Art mice and cultivated these cells for 3 h in transwell
chambers in the presence of medium containing PBS or recombi-
nant mouse CCL19. We observed that cells from EAE-Art mice
presented a significant reduction in the migratory ability com-
pared with EAE mice (Figure 4A). To evaluate whether Art would
interfere with cellular migration by itself, without the involve-
ment of an accessory cell or mechanism, we cultivated dLN cells
from EAE mice for 3 h in transwell chambers with the same stim-
ulus as before. However, some cells were cultivated in the pres-
ence of Art as well as CCL19. We found that the presence of Art
in cultures significantly reduced the migration of encephalito-
genic cells from EAE mice (Figure 4B). To confirm whether cells
from EAE + Art mice retained their encephalitogenic potential,
we induced passive EAE through the adoptive transfer of cells
from EAE and EAE + Art mice. In concordance with our data so
far, we found that mice developed passive EAE either if responder
cells were from EAE or EAE + Art mice (Figure 4C). We did a
final experiment to evaluate whether artesunate-induced EAE
amelioration relied on an anti-migratory potential, and we adop-
tively transferred cells from EAE mice to RAG2/ mice and trea-
ted these mice with Art 3 days later. In contrast to what we
observed in mice recipient of EAE + Art cells, administration of
Art to mice that received cells from untreated EAE mice led to a
milder form of disease compared with untreated mice
(Figure 4D).
Figure 4 Artesunate reduces the migration of cells. Experimental autoimmune encephalomyelitis was induced in C57BL/6 mice (n = 10) through the
immunization with 100 lg of MOG35–55 peptide and 200 ng/mice of pertussis toxin injection at 0 and 48 h from immunization. Mice were divided in two
groups, where one group received artesunate (3 mg/kg) for five consecutive days starting the same day of immunization, and the other group received
vehicle (PBS 0.02M pH7.4). (A) Ten days after immunization, mice were killed and the draining lymph nodes were collected. The organs were disrupted to
prepare single-cell suspensions, which were seeded (5 9 105 cells) on the upper chamber of transwell plates. The lower chamber was filled with complete
medium alone (PBS) or with recombinant mouse CCL19 (20 ng/mL). Cells were incubated for 3 h at 37°C. At the end of culture time, cells in the lower
chamber were counted in hemocytometer. Results are presented as mean  SEM. *P < 0.05 in t-test analysis. (B) Ten days after immunization, EAE-
bearing mice were killed and the spleen cells (5 9 105 cells/insert) were seeded in the upper chamber of a transwell plate. In the lower chamber, RPMI
medium alone (PBS) supplemented with CCL19 (20 ng/mL) with or without artesunate (2.5 lM). The cultures were incubated for 3 h at 37°C. At the end of
incubation time, cells in the lower chamber were counted in hemocytometer. Results are presented as mean  SEM. *P < 0.05 in one-way ANOVA
multiple comparison analysis. (C) Spleen cells from untreated and Art-treated EAE-bearing mice at 10 dpi were adoptively transferred to RAG2/ mice
(5 9 106 cells/mice), and the clinical course of passive EAE was evaluated daily. Results are presented as mean  SEM. (D) Spleen cells from untreated
EAE-bearing mice at 10 dpi were adoptively transferred to RAG2/ mice (n = 12 mice). Group of mice also received Art (3 mg/kg) for five consecutive
days starting day 3 from adoptive transfer. The clinical course of passive EAE was evaluated daily. Results are presented as mean  SEM. *P < 0.05 in
two-way ANOVA multiple comparison analysis. Combined results from three independent experiments with similar observations.
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Discussion
In this study, we show that artesunate present a beneficial effect
on experimental autoimmune encephalomyelitis, model of MS, by
interfering with the cellular infiltration in the CNS. Our data pre-
sent a novel mechanism of action exerted by Art, the inhibition of
cell migration rather than the modulation of the specific inflamma-
tory response. These findings are interesting and shed light on a
possible therapeutic potential of Art in the clinics of MS.
Multiple sclerosis is a human demyelinating disease that is
dependent on the infiltration of inflammatory cells in the CNS
where their products promote tissue damage and axonal death
[1,36]. Therefore, therapies focused on cellular infiltration in the
CNS are of great importance. We observed that Art treatment
starting on the day of disease induction resulted in a mild form of
EAE that did not correlate with altered cellular subpopulations or
reduced cellular responsiveness to encephalitogenic peptide.
Instead, we observed that EAE + Art mice presented higher num-
bers of cells in secondary lymph nodes compared to untreated
EAE mice. This is interesting as the migratory ability of leukocytes
was reduced in these mice as well. Together, these observations
suggest that Art acts through the inhibition of cellular migration
to the sites of inflammation.
Other studies have shown that Art presents a beneficial effect
on the treatment of experimental arthritis models [23,27,37–40].
For instance, Art treatment initiating in the induction phase of
collagen-induced arthritis (CIA) promoted a significant ameliora-
tion in the inflammatory process of the cartilages and that effect
correlated with a diminished infiltration of leukocytes to the joints
[23,37]. Art treatment in CIA promoted a reduction in the serum
levels of TNF-a and the chemotactic factor MCP-1 [40]. Fibrob-
last-like synoviocytes from rheumatoid arthritis patients produced
significantly less IL-8 after Art treatment than untreated cells [39].
It was shown that Art inhibits NF-jB, mitogen-activated protein
kinase and AKT signaling pathways in macrophage cell line
Raw264.7 and human fibroblast-like synoviocytes [38,41].
Notwithstanding, germinal center B cells were reduced while dis-
crete alterations were observed in T-cell subpopulations after Art
treatment in the K/BxN mouse model of rheumatoid arthritis
[27]. Similar results were observed in experimental models of
lupus and colitis [28,29].
We did not find significant alterations in the frequency of Th1/
Th17 and regulatory T cells following Art treatment. We did
observe that IL-10-producing T cells were increased in the CNS of
EAE + Art mice, but not in spleens from healthy mice treated
with Art. One possible hypothesis is that after priming, T cells are
re-activated locally in the CNS by resident cells or antigen-pre-
senting cells [42–45]. That second activation may be necessary to
establish the IL-10-producing cell phenotype in the infiltrating T
cell from EAE + Art mice. Still, we did not follow that line of
investigation in this paper. Of note, bone marrow-derived
dendritic cells (DCs) treated with artesunate and stimulated with
lipopolysaccharide showed similar activation profile (MHC-
IIhighCD80highCD86high) as untreated DCs (data not shown). These
data suggest that Art has little effect on the activation of T cells
and dendritic cells. Literature present data regarding alterations in
macrophages, synoviocytes, and B lymphocytes followed Art
treatment [23,27,39,41]. We did not evaluate these cellular com-
ponents in our study, as EAE is mainly a T cell-driven disease,
although macrophages play an important role.
The main finding in our study is the observation that cells from
EAE + Art mice presented lower expression of chemokine recep-
tors, reduced migratory ability, and did not leave the secondary
lymphoid organs in the course of EAE. Similar results are found in
mice and transplanted/MS patients treated with FTY720 (fin-
golimod) and FK506 (tacrolimus) [46–51]. In our study, we found
that T cells maintained their encephalitogenic potential after Art
treatment, as transfer of cells from EAE + Art mice to RAG2/mice
resulted in normal disease development. This observation is impor-
tant, as Art efficacy may be temporary in MS patients. In this con-
text, accumulating evidence suggest that fingolimod-treated MS
patients that discontinued treatment may present relapses or
rebounds [48,52–54]. Forty-day evaluation of EAE + Art mice
showed that disease worsens after 30 days from treatment discon-
tinuation to the same levels as untreated mice (data not shown). Still,
our data show promising results regarding the use of artesunate in
the treatment of relapsing forms of MS. New studies must be con-
ducted to ascertain the extent of the cellular migration inhibition or
the migration receptors involved in Art-induced EAE amelioration.
Conclusion
Taken together, our data show that Art present a beneficial effect
on experimental autoimmune encephalomyelitis, model of MS.
To our knowledge, we are the first to present a novel mechanism
of action exerted by Art, the inhibition of the cellular migration to
the CNS. New studies must be conducted to evaluate the full
range of migration receptors and cellular subsets involved in Art-
induced EAE amelioration.
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